Pharmacoeconomic review report: Migalastat (Galafold) (Amicus therapeutics)
Migalastat (Galafold) is indicated for the long-term treatment of adults with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) who have an amenable mutation. The recommended dosage is 123 mg every other day at the same time of day. At the submitted price, migalastat at $1,70...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2018, February 2018
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Migalastat (Galafold) is indicated for the long-term treatment of adults with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) who have an amenable mutation. The recommended dosage is 123 mg every other day at the same time of day. At the submitted price, migalastat at $1,700 per capsule is $310,250 annually per patient, which is similar to the publicly available prices of IV enzyme replacement therapy (ERT). The indication for migalastat differs with the indication for ERTs, given the requirement for an amenable mutation for migalastat |
|---|---|
| Physical Description: | 1 PDF file (30 pages) illustrations |